Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

18 Jul 2024 Planned number of patients changed from 51 to 52.
09 Dec 2023 Dana-Farber Cancer Institute Media Release, data from this study will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by the the study's lead author, Omar Nadeem, MD.
09 Dec 2023 Results presented in a Dana-Farber Cancer Institute Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com